AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 191 min read$TEM

Fukushima Ryan sold $49K of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 700 indirectly-held shares of Tempus AI, Inc. (TEM) at $70.00 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Sep 19, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

Small insider sale provides limited insight into company fundamentals.

02

Market read

Minimal relevance; the sale is unlikely to influence trading decisions.

03

What to watch

The transaction size is too small to affect market perception.

Relevance 2/10Novelty 4/10Timing: post filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

CEO Fukushima Ryan sold 700 shares of Tempus AI (TEM) for $49,000 via a 10b5-1 plan.

Expected impact

negligible impact on price

Evidence & confidence

Sale size ($49k) is trivial; pre‑arranged plan reduces informational content.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

Sale could be interpreted as insider confidence because it follows a pre‑arranged plan.

Key entities

  • company
    Tempus AI, Inc.

    AI‑driven healthcare data company (ticker TEM).

  • person
    Fukushima Ryan

    CEO of Tempus AI.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

SEP 17
$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min
SEP 17
$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min
SEP 15
$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min
SEP 5
$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min
SEP 2
$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min